Skip to content

Darunavir effective and tolerable in treatment-experienced children and adolescents at 48 weeks

Bevirimat: good results at 400 mg liquid dose, but formulation problems persist

No significant differences between elvucitabine and 3TC at 48 weeks

Raltegravir non-inferior to efavirenz: 48 week, phase III results

CD4 decline, death more likely if change from NNRTI regimen delayed

Efavirenz superior to nevirapine for first-line treatment: African observational cohort

Is there a role for tropism testing in routine HIV care?

HIV-associated immunosuppression increases risk of liver cancer

Once-daily darunavir (Prezista) approved for first-line use in United States